5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now

2. Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Short Float: 20.87%

Market Cap: $1.65 Billion

Stock Upside Potential: 91.22%

Number of hedge fund holders: 31

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, B Riley reiterated a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) with a $63 price target. The positive stance comes as the company enters into a pivotal stage in the potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy.

The company is staring at a potential FDA review of a Biologics License Application (BLA) and a PDUFA target set for August. The agency has already accepted the company’s Class 2 resubmission as complete. Capricor’s GMP manufacturing facility in San Diego has also completed an FDA Pre-License Inspection, with all Form 483 observations addressed. The facility is to support the initial commercial launch.

Manufacturing expansion is expected in the first half of 2027, up from the previous late 2027 timeline. Capricor also remains in a solid financial position to cover anticipated expenses and capital requirements through Q4 2027, excluding any potential revenue from product sales.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare and serious diseases. Their primary focus is treating Duchenne muscular dystrophy (DMD) through regenerative and anti-inflammatory medicine.